Crescent Biopharma Posts -74.58% ROIC Versus 9.98% WACC
Crescent Biopharma reported a Return on Invested Capital of -74.58% versus a 9.98% Weighted Average Cost of Capital, producing a ROIC/WACC ratio of -7.47. This places Crescent Biopharma at the bottom of peer rankings, with only Pieris Pharmaceuticals achieving positive capital efficiency (22.28% ROIC over 7.52% WACC).
1. Sharp Negative ROIC
Crescent Biopharma reported a Return on Invested Capital of -74.58% against a 9.98% Weighted Average Cost of Capital. The resulting ROIC/WACC ratio of -7.47 indicates the company is generating returns far below its cost of capital.
2. Peer Benchmarking
In the peer analysis, Pieris Pharmaceuticals leads with a 22.28% ROIC over a 7.52% WACC, yielding a ratio of 2.96. CytomX Therapeutics also shows positive capital efficiency with an 18.76% ROIC against a 15.09% WACC, while Galmed Pharmaceuticals, Cidara Therapeutics and MacroGenics report negative ROICs less severe than Crescent Biopharma.
3. Financial Implications
Such pronounced capital inefficiency may pressure Crescent Biopharma to secure additional financing at higher costs or dilute existing shareholders. Investors may view these metrics as a risk factor when assessing the company's valuation and funding strategy.